Post-intervention vessel remodeling.
By-pass surgery and percutaneous transluminal (coronary) angioplasty, PT(C)A, are standard techniques for the treatment of vascular occlusions. Their usefulness is limited by by-pass graft failure and restenosis occurring after the procedures. Twenty percent of patients treated with PTCA/PTA need a new revascularization procedure within 6 months, despite a successful procedure. Stents are used to prevent restenosis in selected lesions, but in-stent restenosis also remains an important clinical problem. In this review we discuss progress of gene therapy for the treatment of post-PT(C)A restenosis, in-stent restenosis and by-pass graft stenosis over the last 2 years (2000-2002).
Rutanen
J
J
AI Virtanen Institute, University of Kuopio, Finland.
Puhakka
H
H
Ylä-Herttuala
S
S
D000818:Animals; D003327:Coronary Disease / Q000628:therapy; D023903:Coronary Restenosis / Q000473:pathology / Q000628:therapy*; D016228:Endothelial Growth Factors / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D006083:Graft Occlusion, Vascular / Q000628:therapy*; D006801:Humans; D006965:Hyperplasia; D023421:Models, Animal; D009204:Myocardial Revascularization; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D014161:Transduction, Genetic / Q000379:methods; D017539:Tunica Intima / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A
D016228:Endothelial Growth Factors; D016376:Oligonucleotides, Antisense; D016271:Proto-Oncogene Proteins c-myc; D042461:Vascular Endothelial Growth Factor A